Common use of Research Practice Clause in Contracts

Research Practice. 3.1 The Institution and the Grantholder will at all times during the continuance of the Agreement comply with: 3.1.1 the Policies; 3.1.2 the terms of the Agreement; and 3.1.3 any laws and regulations (as amended from time to time) applicable to the Project and the Agreement including human tissue legislation, health & safety legislation, the Data Protection Legislation and the Bribery Act 2010. 3.2 It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. 3.3 If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Project, or in relation to the Grantholder (or any other person involved in the Project) in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): 3.3.1 Requiring the Institution to remove the Grantholder (or any other person involved in the Project) from the Project; 3.3.2 Requiring the Institution and/or Grantholder to retract published material; 3.3.3 withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; 3.3.4 taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; 3.3.5 terminating the Grant with immediate effect. 3.4 The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇.▇▇/highereducation/Documents/2012/TheConcordatToSup portResearchIntegrity.pdf) 3.5 Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will promptly upon request provide copies of such approvals, licences and consents to Diabetes UK. 3.6 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of ethical issues connected to the Project, and that such issues are dealt with in accordance with such procedures. The Institution will notify Diabetes UK of any ethical issues connected to the Project and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.7 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of potential conflicts of interest in connection with the Project. The Institution will notify Diabetes UK of any conflicts of interest that arise and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.8 The Institution will promptly notify Diabetes UK of any incident connected to the Project (which the Institution at its reasonable discretion considers relevant to Diabetes UK’s rights and interests in the Project), and will keep Diabetes UK promptly informed of any developments connected to such incident. 3.9 The Institution warrants that full details of any third party funding granted to it in connection with the Project were included in the Application Form and Institution agrees, if any such funding is obtained subsequently to Diabetes UK’s acceptance of the Application Form, that it will promptly notify Diabetes UK in writing with full details of such funding. 3.10 The Institution warrants that the Application Form has disclosed to the best of its knowledge any rights (other than to not-for-profit institutions for non-commercial research use) it has granted to third parties over Intellectual Property existing on the date the Application Form was accepted for funding by Diabetes UK and which may hinder or prevent the implementation of the Project or the subsequent commercial exploitation of Grant Funded Intellectual Property and will not grant any such rights after the acceptance of the Application Form without the prior written consent of Diabetes UK.

Research Practice. 3.1 The Institution and the Grantholder will at all times during the continuance of the Agreement comply with: 3.1.1 the Policies; 3.1.2 the terms of the Agreement; and 3.1.3 any laws and regulations (as amended from time to time) applicable to the Project and the Agreement including human tissue legislation, health & safety legislation, the Data Protection Legislation and the Bribery Act 2010. 3.2 It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. 3.3 If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Project, or in relation to the Grantholder (or any other person involved in the Project) in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): 3.3.1 Requiring the Institution to remove the Grantholder (or any other person involved in the Project) from the Project; 3.3.2 Requiring the Institution and/or Grantholder to retract published material; 3.3.3 withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; 3.3.4 taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; 3.3.5 3.3.3 terminating the Grant with immediate effect. 3.4 The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (▇▇▇▇://▇▇▇policy.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇.▇▇/highereducation/Documents/2012/TheConcordatToSup portResearchIntegrity.pdf) 3.5 Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will promptly upon request provide copies of such approvals, licences and consents to Diabetes UK. 3.6 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of ethical issues connected to the Project, and that such issues are dealt with in accordance with such procedures. The Institution will notify Diabetes UK of any ethical issues connected to the Project and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.7 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of potential conflicts of interest in connection with the Project. The Institution will notify Diabetes UK of any conflicts of interest that arise and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.8 The Institution will promptly notify Diabetes UK of any incident connected to the Project (which the Institution at its reasonable discretion considers relevant to Diabetes UK’s rights and interests in the Project), ) and will keep Diabetes UK promptly informed of any developments connected to such incident. 3.9 The Institution warrants that full details of any third party funding granted to it in connection with the Project were included in the Application Form and Institution agrees, if any such funding is obtained subsequently to Diabetes UK’s acceptance of the Application Form, that it will promptly notify Diabetes UK in writing with full details of such funding. 3.10 The Institution warrants that the Application Form has disclosed to the best of its knowledge any rights (other than to not-for-profit institutions for non-commercial research use) it has granted to third parties over Intellectual Property existing on the date the Application Form was accepted for funding by Diabetes UK and which may hinder or prevent the implementation of the Project or the subsequent commercial exploitation of Grant Funded Intellectual Property and will not grant any such rights after the acceptance of the Application Form without the prior written consent of Diabetes UK.

Research Practice. 3.1 The Institution and the Grantholder will at all times during the continuance of the Agreement comply with: 3.1.1 the Policies; 3.1.2 the terms of the Agreement; and 3.1.3 any laws and regulations (as amended from time to time) applicable to the Project and the Agreement including human tissue legislation, health & safety legislation, the Data Protection Legislation and the Bribery Act 2010▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇. 3.2 It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. 3.3 If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Project, or in relation to the Grantholder (or any other person involved in the Project) in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): 3.3.1 Requiring the Institution to remove the Grantholder (or any other person involved in the Project) from the Project; 3.3.2 Requiring the Institution and/or Grantholder to retract published material; 3.3.3 withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; 3.3.4 taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; 3.3.5 terminating the Grant with immediate effect. 3.4 The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇.▇▇/highereducation/Documents/2012/TheConcordatToSup portResearchIntegrity.pdfTheConcordatToSupport ResearchIntegrity.pdf) 3.5 Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will promptly upon request provide copies of such approvals, licences and consents to Diabetes UK. 3.6 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of ethical issues connected to the Project, and that such issues are dealt with in accordance with such procedures. The Institution will notify Diabetes UK of any ethical issues connected to the Project and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.7 The Institution will ensure that it has in place throughout the Grant Period procedures for the identification and management of potential conflicts of interest in connection with the Project. The Institution will notify Diabetes UK of any conflicts of interest that arise and will keep Diabetes UK informed of any actions taken in relation to such issues. 3.8 The Institution will promptly notify Diabetes UK of any incident connected to the Project (which the Institution at its reasonable discretion considers relevant to Diabetes UK’s rights and interests in the Project), and will keep Diabetes UK promptly informed of any developments connected to such incident. 3.9 The Institution warrants that full details of any third party funding granted to it in connection with the Project were included in the Application Form and Institution agrees, if any such funding is obtained subsequently to Diabetes UK’s acceptance of the Application Form, that it will promptly notify Diabetes UK in writing with full details of such funding. 3.10 The Institution warrants that the Application Form has disclosed to the best of its knowledge any rights (other than to not-for-profit institutions for non-commercial research use) it has granted to third parties over Intellectual Property existing on the date the Application Form was accepted for funding by Diabetes UK and which may hinder or prevent the implementation of the Project or the subsequent commercial exploitation of Grant Funded Intellectual Property and will not grant any such rights after the acceptance of the Application Form without the prior written consent of Diabetes UK.